# A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

> **NCT05999994** · PHASE2 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 105 (estimated)

## Conditions studied

- Neoplasms
- Child
- Adolescent

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Abemaciclib
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05999994
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-22
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999994, "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05999994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*